key: cord-0743730-lfwi3zbq authors: Masuccio, Fabio Giuseppe; Tipa, Virginia; Invernizzi, Marco; Solaro, Claudio title: Guillain-Barré Syndrome Related and Unrelated to COVID-19: Clinical Follow-Up in the COVID-19 Era date: 2022-05-03 journal: Phys Ther DOI: 10.1093/ptj/pzac049 sha: 7564b357e83c098a8c7686c1078df6a22c5adeb2 doc_id: 743730 cord_uid: lfwi3zbq OBJECTIVE: COVID-19 has been associated with neurological complications such as Guillain-Barre syndrome (GBS). Several cases have been reported, but without functional outcome data after intensive rehabilitation and medium-term follow-up. METHODS: In this observational study, patients were admitted in 2019 and 2020 to inpatient rehabilitation for GBS and were examined using the Barthel index, GBS-Disability Scale, and Medical Research Scale-sum score at admission, discharge, and at least 6 months after onset of symptoms. All the participants received personalized, goal-oriented inpatient rehabilitative treatment for the recovery of self-sufficiency in everyday life. RESULTS: Eleven people with GBS—3 cases related to COVID-19—were admitted in 2019 and 2020 to inpatient rehabilitation. Eight patients with GBS not related to COVID-19 experienced a high complication rate during inpatient rehabilitation, with 2 deaths due to sepsis. In this cohort, a higher prevalence than expected of acute motor axonal neuropathy was also detected. The COVID-19–related GBS (C-GBS) group did not have any complications. After a mean of 10.11 months (SD = 4.46 mo), 55.55% of patients regained autonomous walking. CONCLUSION: COVID-19–related GBS appeared to have a better clinical outcome than GBS that was not COVID-19 related (NC-GBS). A higher than usual prevalence of acute motor axonal neuropathy form was encountered. More follow-up studies are needed to understand whether the recovery of GBS related to COVID-19 might be different from that of GBS unrelated to COVID-19. IMPACT: No data are currently available on the follow-up of Guillain-Barré syndrome in the COVID-19 era and on the functional outcome of those patients. This study provides important information indicating that GBS related to COVID-19 might have a better clinical outcome than GBS unrelated to COVID-19. The pandemic spreading of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) overwhelmed health care systems worldwide. Considered a respiratory disease, coronavirus disease (COVID-19) has also provoked neurological manifestations, 1 such as Guillain-Barrè syndrome (GBS). [2] [3] [4] GBS is an acute autoimmune neurological disease involving the peripheral nervous system, (global yearly prevalence = 0.8-1.9 cases per 100,000 people). 5 The principal clinical feature is an acute or subacute onset of progressive weakness in the 4 limbs, potentially involving the respiratory muscles and needing mechanical ventilation. GBS is often preceded by a respiratory or gastrointestinal infection, usually 2 or 3 weeks before symptom onset. 5 The electrophysiological pattern formerly defines a demyelinating and an axonal variant, that is, an acute inflammatory demyelinating polyradiculopathy (AIDP) and an acute motor axonal neuropathy (AMAN), although mixed forms can be detected. 5 Some authors theorized that SARS-CoV-2 might cause GBS with both a para-infectious and a postinfectious mechanism of action, 6,7 but this has not been confirmed yet. Although several COVID-19-associated GBS (C-GBS) cases have been reported, 2, 3, 6, 8, 9 data are lacking on the follow-up of C-GBS and non-COVID-19-associated GBS (NC-GBS) after neurology department discharge. In this article, we present the functional outcomes of the patients admitted to an inpatient rehabilitation unit for GBS in 2019 and 2020, and the follow-up performed at least 6 months from symptom onset. The intensity of the exercise was gradually increased according to tolerance. Gait and cardiovascular resistance training were begun as soon as possible, also utilizing exercise bicycle and treadmill training. Periodic resting was used to avoid fatigue. Eleven cases (all, mean age = 71.89 years [SD = 9. All patients with C-GBS regained satisfactory upper limb utilization, feeding themselves independently since rehabilitation discharge. In the NC-GBS group, 1 patient had a recognizable source of infection (herpes zoster virus). One patient was treated with plasma exchange, and the other with IVIG. Two patients had AIDP, 5 had AMAN, and 1 had an AMAN/AIDP mixed form. In the NC-GBS group, a high rate of complications occurred during inpatient rehabilitation. Two patients had a chronic obstructive pulmonary disease (COPD) exacerbation, and 1 had lobar pneumonia. Urinary tract infections (UTIs) were detected in 2 patients, and the younger patient had a myocardial infarction with nonobstructive coronary artery disease. In 1 case, readmission to hospital and IVIG treatment was needed due to GBS recurrence, with subsequent readmission to rehabilitation. Unfortunately, 2 of the patients with AMAN died due to sepsis. GBS can be associated with long-term disability, potentially limited through inpatient intensive and outpatient rehabilitation. 11 Due to the necessity to reallocate resources in the acute care setting, 2020 was characterized by several difficulties in delivering rehabilitation services. In Piedmont, several inpatient rehabilitative centers had been converted into COVID-19-units to handle the pandemic. In this context, rehabilitation represented a crucial player in fighting disability. 14 Two systematic reviews on C-GBS have been published, 2, 4 but no data on medium-term functional outcome during the COVID-19-era are available. This study reports on the followup of patients with C-GBS after inpatient rehabilitation and at least 6 months after symptom onset. The evaluation involved the use of 3 well-validated scales for the examination of patients affected with GBS. In particular, the GBS-DS is accepted at an international level, being included in the Erasmus GBS outcome score. 15 Functional recovery appeared more successful in C-GBS patients. Patients with AIDP showed a benign course at T1 and T2 with an excellent recovery in terms of MRC-ss, BI, and GBS-DS scores, whereas the patient with AMAN had a partial recovery, possibly negatively influenced by a concomitant myelitis. 13 In C-GBS, we expected negative effects on rehabilitation because of the possible delay in admission to neurorehabilitation, 16 with the necessity of a negative RT-PCR nasopharyngeal swab and a fully stable clinical condition. In fact, in Piedmont, very few rehabilitation departments have been dedicated to patients with positive swab results, and it must be considered that the risk of respiratory complications might be higher in patients with COVID-19. However, we found that these factors did not influence recovery. Conversely, patients with NC-GBS experienced an unexpected high rate of complications and an AMAN prevalence higher than usual (6 patients with axonal damage, 1 with mixed AMAN/AIDP form). These factors might feasibly explain the poorer functional outcome in this cohort. 5 In fact, it is well recognized not only that AMAN forms are associated with a worse recovery, 5 but also that medical complications during neurorehabilitation are linked to worse rehabilitative and quoad-vitam prognoses. All patients received personalized physical therapist and occupational therapist treatment during the length of stay. In this regard, it could be argued that the number of rehabilitation hours might have affected the recovery. In particular, Barthel Index scores might have been influenced by occupational therapy. Due to the nature of this report, however, we are unable to give further consideration to these possible relationships. The most important factors influencing a worse recovery might have been represented by the complications encountered and the GBS subtype; however, this is a single-center experience and not a population-based study, and epidemiological deduction is not appropriate. The capacity to walk autonomously, a key feature in these individuals' independence, was reached in 55.5% of the cases. In 1 case, walking was possible with help (11.1%). This proportion remained the same at T2, as the worsening of COPD compromised 1 patient's ability to march autonomously, whereas another patient regained this ability after outpatient rehabilitation. The observation is in line with a recent study, 11 in which the 58.5% of the patients reacquired autonomous walking ability after 3 months since discharge from an intensive rehabilitation facility and subsequent outpatient rehabilitation. In our report, only 3 of 9 patients continued rehabilitation in an outpatient setting. In this respect, the forced closure of some of the local rehabilitative services in the COVID-19 lockdown period might have contributed to the rise of the GBS disability burden. In summary, the medium-term follow-up revealed a better functional outcome of the C-GBS group, compared with a NC-GBS group that had a higher-than-expected rate of AMAN and complications, which might have easily caused an inferior recovery. The small sample represents a limitation-specifically, excluding further speculation on the functional outcome of these patients and allowing only a descriptive analysis of the medium-term follow-up. Longitudinal studies are needed to identify whether C-GBS or NC-GBS might have substantial differences in terms of onset and recovery. Analyzing the follow-up of neurological complications is mandatory to refine the methods of treatment and understand the prognosis of these patients more accurately. Furthermore, addressing the pitfalls in the management of the neurological pathologies is also necessary in the COVID-19 era, as rehabilitation is an essential step toward disability reduction. The Ethics Committee considered this manuscript as an observational case series that did not require approval. All the patients gave written informed consent for the inclusion of anonymized clinical data in a scientific publication, in agreement with the Declaration of Helsinki. The authors received Ethical Committee approval for the study of COVID-19 and related consequences. There are no funders to report for this study. The authors completed the ICMJE Form for Disclosure of Potential Conflicts of Interest and reported no conflicts of interest. Neurological manifestations and neuro-invasive mechanisms of the severe acute respiratory syndrome coronavirus type 2 Guillain Barre' Syndrome and its variants as a manifestation of COVID-19: A systematic review of case reports and case series Guillain-Barre syndrome during SARS-CoV-2 pandemic: a case report and review of recent literature Guillain-Barré syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases Guillain-Barré syndrome Guillain-Barré Syndrome Associated with SARS-CoV-2 Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence? Guillain-Barré syndrome in the COVID-19 era: just an occasional cluster? Guillain-Barré syndrome in the COVID-19 era Functional evaluation: the Barthel Index Importance of intensive and prolonged rehabilitative treatment on the Guillain-Barrè syndrome long-term outcome: a retrospective study Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barré syndrome A rare case of acute motor axonal neuropathy and myelitis related to SARS-CoV-2 infection Disability through COVID-19 pandemic: neurorehabilitation cannot wait A clinical prognostic scoring system for Guillain-Barré syndrome The role of physical and rehabilitation medicine in the COVID-19 pandemic: The clinician's view